Pfizer (PFE) Cash & Current Investments (2009 - 2026)

Pfizer has disclosed Cash & Current Investments across 18 years of filings, most recently posting $13.1 billion for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 24.5% year-over-year to $13.1 billion; the TTM figure through Mar 2026 stood at $13.1 billion (down 24.5% YoY), while the FY2025 annual figure was $13.6 billion, down 33.6% from the prior year.
• Cash & Current Investments declined to $13.1 billion in Q1 2026, from $13.6 billion in the prior quarter.
• Over the last five years, Cash & Current Investments for PFE reached as high as $44.8 billion in Q3 2023 and fell as low as $7.1 billion in Q2 2024.
• The 5-year median for Cash & Current Investments is $17.3 billion (2025), against an average of $21.1 billion.
• Annual changes were most pronounced in 2024 — Cash & Current Investments plunged 84.15% — and 2025, when it surged 86.61%.
• A 5-year view of Cash & Current Investments shows it stood at $22.7 billion in 2022, then tumbled by 44.18% to $12.7 billion in 2023, then surged by 61.36% to $20.5 billion in 2024, then sank by 33.6% to $13.6 billion in 2025, then retreated by 3.83% to $13.1 billion in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $13.1 billion, $13.6 billion, and $15.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.